| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/16/2006 | WO2005097132A3 Methods of treatment using eszopiclone |
| 02/16/2006 | WO2005097107A8 Diphenyl - indol-2-on compounds and their use in the treatment of cancer |
| 02/16/2006 | WO2005094333A3 Multi-vitamin and mineral nutritional supplements |
| 02/16/2006 | WO2005090287A3 Phenylethanolamine derivatives as beta-2 agonists |
| 02/16/2006 | WO2005080352A3 Quinazoline derivatives and therapeutic use thereof |
| 02/16/2006 | WO2005077019A3 Protease inhibitors for treatment of wrinkles |
| 02/16/2006 | WO2005067899A3 Methods for treating stress and affecting biological immune systems using a cysteamine compound |
| 02/16/2006 | WO2005062748A3 Bicyclic carbohydrate compounds useful in the treatment of infections caused by herpesviridae |
| 02/16/2006 | WO2005055941A3 Novel m3 muscarinic acetylcholine receptor antagonists |
| 02/16/2006 | WO2005048957A3 Novel insertion sites in pox vectors |
| 02/16/2006 | WO2005039573A3 Biomarkers for the prediction of drug-induced diarrhoea |
| 02/16/2006 | WO2005030083A3 Methods and products which utilize n-acyl-l-aspartic acid |
| 02/16/2006 | WO2005002545A8 Method of treating acute coronary syndromes |
| 02/16/2006 | WO2005002525A3 Cox-2 and faah inhibitors |
| 02/16/2006 | WO2004110378A3 Treatment alzheimer's disease with r(-) 2-arylproponic acid nsaid alone or in combination with selective cox-2 inhibitor |
| 02/16/2006 | WO2004110359A9 Fusion proteins for the treatment of cns |
| 02/16/2006 | WO2004094373A3 A method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith |
| 02/16/2006 | WO2004082599A3 Combination of an aldosterone receptor antagonist and an anti-diabetic agent |
| 02/16/2006 | WO2004071430A3 RNAi TARGETING OF VIRUSES |
| 02/16/2006 | WO2004043384A3 Novel pharmacophore for the discovery and testing of na, k-atpase inhibitor compositions and methods for their use in treating cardiovascular diseases and conditions |
| 02/16/2006 | WO2004024095A3 ß-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES |
| 02/16/2006 | WO2003083058A3 Replikin peptides in rapid replication of glioma cells and in influenza epidemics |
| 02/16/2006 | US20060036110 reacting hydrogen sulfide with epoxidized vegetable oils, in the presence of catalysts, to form mercaptohydroxy vegetable oils; chemical intermediates for polythiourethanes used in fertilizers coatings |
| 02/16/2006 | US20060036098 Carbonylamino-benzimidazole derivatives as androgen receptor modulators |
| 02/16/2006 | US20060036094 Method for producing zoanthamine alkaloid and intermediate used in same |
| 02/16/2006 | US20060036093 Pyrimidinone compounds |
| 02/16/2006 | US20060036091 synthetic metabolites of CCI-779; for detecting CCI-779 metabolites in samples; generating CCI-779 reduction and hydroxylation derivatives using a CYP3A4 isozyme system |
| 02/16/2006 | US20060036089 33 human secreted proteins |
| 02/16/2006 | US20060035984 Method of inhibiting formation of neisseria gonorrhea and neisseria meningiditis |
| 02/16/2006 | US20060035983 Methods for treating fungal infections |
| 02/16/2006 | US20060035982 Method for promoting blood stream |
| 02/16/2006 | US20060035981 Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment |
| 02/16/2006 | US20060035980 Thyronamine derivatives and analogs and methods of use thereof |
| 02/16/2006 | US20060035979 Inhibitors of transcription factor NF-kappaB |
| 02/16/2006 | US20060035977 Uses of acylated aminopropanediols and sulphur and nitrogen analogues of same f |
| 02/16/2006 | US20060035976 Methods of preventing headaches with norepinephrine precursors |
| 02/16/2006 | US20060035975 coated dosage forms of capsule, a tablet contains ethylenediamine tetraacetic acid, and on surface cathode and anode protruding from the surface thereof; creating a galvanic current upon contact of the dosage, release the acid to dissolve the stone; controlled release |
| 02/16/2006 | US20060035974 Linoleic acid active agents for enhancing probability of becoming pregnant |
| 02/16/2006 | US20060035973 Pharmaceutical composition for intracellular acidification with cis-urocanic |
| 02/16/2006 | US20060035972 Therapeutic compositions and uses |
| 02/16/2006 | US20060035971 Blood fluidity improving agent |
| 02/16/2006 | US20060035970 4-(4-benzyloxy-3-chlorophenyl)-4-oxobutanoic acid; Methyl 4-(4-benzyloxy-2-methoxyphenyl)-4-oxobutanoate or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis |
| 02/16/2006 | US20060035969 Novel modulators of the PPAR-type receptors and cosmetic/pharmaceutical compositions comprised thereof |
| 02/16/2006 | US20060035968 Composition for preventing cancer comprising 2'-benzoyl-oxycinnamaldehyde |
| 02/16/2006 | US20060035966 Irreversible selective androgen receptor modulators and methods of use thereof |
| 02/16/2006 | US20060035965 N-phenyl-2-hydroxy-2-methyl-3-(p-cyano)phenoxypropamides; spermatogenesis inhibitors, hormone replacement therapy, bone and metabolic disorders; antidiabetic agents; obesity |
| 02/16/2006 | US20060035964 Hypoglycemic agent, liver protecting agent and anticancer agent containing lignans originating in hongdoushan |
| 02/16/2006 | US20060035963 Quinone prodrug compositions and methods of use |
| 02/16/2006 | US20060035962 Method and compositions for preparing a compound using a benzoylating agent essentially free of ring chlorination |
| 02/16/2006 | US20060035961 Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| 02/16/2006 | US20060035960 Compounds for prodrug for bonding, using prostaglandins |
| 02/16/2006 | US20060035959 e.g. (dibenzofuran-4-yl)-(3,5-dichlorophenylamino)acetic acid; glycine B antagonist on the NMDA receptor complex for regulating the calcium balance; analgesic,antiinflammatory, antidepressant, anxiolytic agent, neurodegenerative diseases; chronic and neuropathic pain |
| 02/16/2006 | US20060035958 Method of treating diabetes and related conditions |
| 02/16/2006 | US20060035957 Preventive or remedy for bedsore |
| 02/16/2006 | US20060035956 Indole derivatives comprising an acetylene group |
| 02/16/2006 | US20060035955 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| 02/16/2006 | US20060035954 Ammonolysis process for the preparation of intermediates for DPP IV inhibitors |
| 02/16/2006 | US20060035953 Cyclizing an N-carboxymethyl-N-alkanoyl-3-formyl-2-thiophenylamine and optionally amidating the product |
| 02/16/2006 | US20060035952 Photosensitizer formulations and their use |
| 02/16/2006 | US20060035951 anticancer, antitumor agents; 1-(3-fluorophenyl)-N-[3(5)-phenylpyrazol-5(3)-yl]-1H-benzimidazole-5-carboxamide; SCF-induced tyrosine phosphorylation of Kit in intact H526 cells; inhibit the tyrosine kinase activity of c-Kit |
| 02/16/2006 | US20060035950 Novel processes for preparing substantially pure anastrozole |
| 02/16/2006 | US20060035949 Compounds for prodrug for bonding, using prostaglandins |
| 02/16/2006 | US20060035948 e.g. 6-nitro-4-[N-(4-chlorophenyl)-N-(2-methyl-2H-tetrazol-5-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran; protecting neuronal cells from oxidative stress induced cell death by iron or by hydrogen peroxide; antihypoxic agent, neuroprotectant |
| 02/16/2006 | US20060035946 Amyloid-binding, metal-chelating agents |
| 02/16/2006 | US20060035945 Prevent reproduction, infection of virus; antitumor agents |
| 02/16/2006 | US20060035944 Remedies for neurodegenerative diseases |
| 02/16/2006 | US20060035943 E.g., 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders |
| 02/16/2006 | US20060035941 Calcium salts of indole derived statins |
| 02/16/2006 | US20060035940 (S)-Amlodipine malate |
| 02/16/2006 | US20060035939 3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity |
| 02/16/2006 | US20060035938 2-Pyridone derivatives as inhibitors of neutrophile elastase |
| 02/16/2006 | US20060035937 (1S,5S)-3-(5,6-dichloropyridin-3-YL)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate |
| 02/16/2006 | US20060035936 Pain and disorders associated with the nicotinic acetylcholine receptor |
| 02/16/2006 | US20060035935 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 02/16/2006 | US20060035934 Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor |
| 02/16/2006 | US20060035933 Compounds having beta adrenergic receptor agonist and muscarinic receptor antagonist activity |
| 02/16/2006 | US20060035932 N-aryl piperidine compounds |
| 02/16/2006 | US20060035931 crystalline 1,2-ethanedisulfonic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl}-5-methoxyphenylcarbamoyl)ethyl]piperidin-4-yl ester; treat a pulmonary disorder |
| 02/16/2006 | US20060035930 4-(2,4-dichloro-5-methoxyphenyl)amino-6-methoxy-7-{[5-substituted -amino)methyl]-3-furyl}-3-quinolinecarbonitriles as kinase inhibitors |
| 02/16/2006 | US20060035929 Compositions and methods containing substituted quinolines and substituted diphenylsulfones |
| 02/16/2006 | US20060035928 for diabetes mellitus and other metabolic disorders; compounds of given formula such as sulfonamides and an antidiabetic agent such as sulfonylureas, biguanides, glitazones, alpha-glucosidase inhibitors, glucagon antagonists |
| 02/16/2006 | US20060035927 administering to a patient suffering from bone disorder, a calcilytic compound, such as N-[(2R-Hydroxy-3-[(3-chloro-2-cyano)phenoxy-propyl]-1,1-dimethyl-2-(2-naphthyl)ethyl amine hydrochloride, in conjunction with an effective amount of an anti-resorptive agent. |
| 02/16/2006 | US20060035926 Benzothiazolium compounds |
| 02/16/2006 | US20060035925 Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 02/16/2006 | US20060035924 Daily melatonin dosing units |
| 02/16/2006 | US20060035923 Overactive bladder treating drug |
| 02/16/2006 | US20060035922 pyrazolyl-[(triazolopyridinylsulfanyl)-benzyl]-urea derivatives; antiinflammatory agents; resiratory disorders, asthma, allergies; N-{3-tert-Butyl-1-[4-(methylthio)phenyl]-1H-pyrazol-5-yl}-N'-{2-[(3-isopropyl [1 ,2,4]triazolo[4,3-a]pyridin-6-yl)thio]benzyl}urea |
| 02/16/2006 | US20060035921 N3-substituted imidazopyridine c-Kit inhibitors |
| 02/16/2006 | US20060035920 Chk-1 inhibitors |
| 02/16/2006 | US20060035919 4-[4-(4-Amino-phenyl)-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl]-benzoic acid methyl ester; rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis; CD80 antagonists capable of inhibiting the interactions between CD80 and CD28 |
| 02/16/2006 | US20060035918 Use of tacrolimus (fk506) derivatives combined with beta2-agonists for the treatment of asthma |
| 02/16/2006 | US20060035917 Inhibits morphine tolerance caused by repeated administration of morphine, while not affecting the analgesic effects of morphine upon a single administration |
| 02/16/2006 | US20060035916 2,4-Pyrimidinediamine compounds and their uses |
| 02/16/2006 | US20060035915 Non-sedating barbituric acid derivatives |
| 02/16/2006 | US20060035914 Compositions and methods for the treatment of disorders of the central and peripheral nervous systems |
| 02/16/2006 | US20060035913 Method for the production of 2-amino-4-chloro-6-alkoxypyrimidines |
| 02/16/2006 | US20060035912 Pyrrolopyrimidine derivatives useful in cancer treatment |
| 02/16/2006 | US20060035911 Method of improved diuresis in individuals with impaired renal function |
| 02/16/2006 | US20060035910 Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives |
| 02/16/2006 | US20060035909 2,6,9-trisubstituted 8-azapurines such as 2-(4-aminocyclohexylamino)-6-benzylamino-9-isopropyl-8-azapurine, used as cyclin-dependent kinase inhibitors, in the treatment of skin disorders, viral infections, cancer, arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, gout |